Table 1 Aurora-A positive tumor cell fraction (%, by IHC) across tumor characteristics and breast cancer subtypes

Aurora-A IHC in-house cohort (n = 292)

Age

 < 40

17 (23.6)

12 (16.7)

20 (27.8)

23 (31.9)

NS

40–49

63 (28.8)

53 (24.2)

53 (24.2)

50 (22.8)

Tumor size

 ≤ 20 mm

48 (29.5)

35 (21.5)

44 (26.9)

36 (22.1)

NS

 > 20 mm

31 (25.0)

28 (22.6)

28 (22.6)

37 (29.8)

LN status

Negative

48 (31.8)

30 (19.9)

35 (23.2)

38 (25.1)

NS

Positive

31 (22.8)

33 (24.3)

37 (27.2)

35 (25.7)

Histologic grade

1 or 2

66 (34.6)

51 (26.7)

48 (25.1)

26 (13.6)

 < 0.001

o3

9 (10.5)

12 (14.0)

21 (24.4)

44 (51.1)

ER status

Positive

65 (32.8)

49 (24.8)

50 (25.3)

34 (17.1)

 < 0.001

Negative

15 (16.1)

16 (17.2)

23 (24.7)

39 (42.0)

PR status

Positive

64 (32.5)

55 (27.9)

48 (24.4)

30 (15.2)

 < 0.001

Negative

16 (17.0)

10 (10.6)

25 (26.6)

43 (45.8)

HER2 status

Positive

8 (16.7)

7 (14.6)

15 (31.2)

18 (37.3)

0.035

Negative

72 (29.7)

58 (24.0)

58 (24.0)

54 (22.3)

Molecular subtypes IHC

Luminal A

53 (46.9)

34 (30.1)

20 (17.7)

6 (5.3)

 < 0.001

Luminal B

14 (16.5)

18 (21.2)

29 (34.1)

24 (28.2)

Luminal B HER2 + 

4 (16.0)

7 (28.0)

6 (24.0)

8 (32.0)

HER2 + non Luminal

4 (17.4)

0 (0)

9 (39.1)

10 (43.5)

Triple Negative

5 (11.7)

6 (13.7)

9 (20.5)

24 (54.1)

Molecular subtypes by PAM50*

Luminal A

14 (34.1)

15 (36.6)

5 (12.2)

7 (17.1)

0.003

Luminal B

8 (28.6)

4 (14.2)

8 (28.6)

8 (28.6)

HER2-Enriched

2 (9.0)

3 (13.5)

8 (36.6)

9 (40.9)

Basal-like

2 (7.7)

3 (11.5)

8 (30.8)

13 (50.0)

Risk groups*

Low risk

8 (47.0)

6 (35.3)

1 (5.9)

2 (11.8)

0.004

Intermediate risk

7 (26.9)

8 (30.8)

5 (19.2)

6 (23.1)

High risk

11 (14.9)

11 (14.9)

23 (31.0)

29 (39.2)

Ki67 status

Low

60 (45.8)

37 (28.2)

26 (19.9)

8 (6.1)

 < 0.001

High

19 (12.0)

27 (17.1)

47 (29.7)

65 (41.2)